CoreNTech Develops Technology to Prevent Artificial Joint Surface Aging... Entering Clinical Trial Stage

원본보기 아이콘

[Asia Economy Reporter Lee Gwan-joo] Corentec announced on the 14th that it has developed a technology for the first time to prevent the biologic aging phenomenon on the surface of artificial hip joints and is entering the clinical trial stage.

Titanium, a metal widely used in artificial joint materials including orthopedic implants, often experiences biologic aging over time, causing problems such as poor bone fusion.

Corentec explained that it recently secured technology to solve this problem through technical cooperation with the bio plasma deep-tech company "Plasmap." Specifically, Plasmap developed a technology that can remove hydrocarbons accumulated due to biologic aging, and Corentec's research team developed a commercialization technology that can prove the excellent hydrophilicity and bone fusion ability of plasma-treated artificial joint surfaces, enabling its application in clinical settings.

The plasma surface activation technology restores porous implants, whose bone fusion ability has decreased due to biologic aging, to their optimal condition. It is expected to increase the success rate of artificial joint surgeries and shorten patients' recovery periods.

Seon Kyung-hoon, CEO of Corentec, said, "This technology development is significant in realizing corporate value as our unique technology can improve the quality of life for patients suffering from joint pain," adding, "We will do our best to expand the market in the United States, the largest market for artificial joints, with our products' high technology and quality."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.